| |
|
|
|
Oxford Global , London
2016-05-12
In keeping with Oxford Global’s highly successful life sciences series, an expert panel of over 30 speakers will present a full conference programme covering the topics outlined below. Advances in Immuno-oncology Congress
Day 1 Stream 1 – Discovery and Early Development of Immuno-oncology Therapies - Key therapeutic strategies in immuno-oncology
– Checkpoint inhibitors
– CAR T cell therapies
– Adoptive cell transfer
– Cancer vaccines & oncolytic viral therapies
– Immune receptor agonist antibodies
– BiTe (Bispecific T Cell Engagers) - Targeting the PD-1 pathway and finding alternative therapeutic targets
- Novel technologies to enhance discovery of immunotherapies in oncology
- Molecular oncology updates including B cells
Day 1 Stream 2 – Immuno-Oncology: Therapeutic Approaches, Clinical Research and Clinical Trials - Approaches to clinical trial design & development
- Key safety challenges in cancer immunotherapy clinical trials
- Strategies for effective trial management
- Clinical data & case studies
- Clinical immuno-oncology combinations in different cancers and tumour types
- Establishing partnerships and collaborations
- Biomarkers in immuno-oncology
- Clinical diagnostics & the potential of NGS in immuno-oncology clinical trials
Day 2– Preclinical Development, Assays and Modelling in Immuno-oncology - Preclinical models including humanised mouse models
- Preclinical assay development
- Translational strategies
- Approaches to preclinical combination therapy design
- Reducing toxicity challenges in immuno-oncology therapeutics
- Innovative technologies for immunotherapy
|
|
|
|
|
|
|
|
Organized by:
|
|
OxfordGlobal |
|
|
Invited Speakers:
|
|
2016 Speakers include:- Helen Angell
Senior Scientist, Astrazeneca - Art Brace
Senior Director Discovery Biologics, Five Prime Therapeutics - Ho Cho
Vice President, Biotherapeutics, Celgene - Joe Conner
CSO, Virttu Biologics - Jacqueline Doody
Vice President, Immunology, F-star Biotechnology - Kevin Friedman
Associate Director Immunotherapy, Bluebird Bio - Tariq Ghayur
Distinguished Research Fellow, AbbVie Bioresearch Center - Anand Giddabasappa
Principal Scientist, Pfizer - Stefan Glück
Vice President Global Medical Affairs, Breast, Ovarian, Bladder Cancer and Immuno-Oncology, Celgene - Michael Hanna
Founder, CSO & Chairman Emeritus, Vaccinogen - Namir Hassan
Director, Oncology Research, Immunocore - Timothy Herpin
Vice President, Strategic Partnering & Business Development Oncology, Science & Technology Licensing, AstraZeneca - Marlon Hinner
Director, Immuno-oncology, Pieris Pharmaceuticals - Sophia Karagiannis
Senior Lecturer in Translational Medicine, King’s College School of Medicine - Roman Kischel
Principal Scientist, Amgen - David Krige
Head of Biomarkers, Immunocore - James Legg
Director, Crescendo Biologics - Michael Lisanti
Professor, Institute of Cancer Sciences, University of Manchester - Jennifer Mataraza
Principal Investigator, Oncology Biotherapeutics, Novartis - Chad May
Director, Oncology Research Unit, Pfizer - Elaine Pinheiro
Principal Scientist, MSD - Graham Pockley
CEO Multimmune GmbH; Associate Director, Professor Cancer Immunotherapy & Flow Cytometry, John van Geest Cancer Research Centre - Gavin Thurston
Vice President, Oncology and Angiogenesis Research, Regeneron Pharmaceuticals - Robert Wilkinson
Director of Oncology Research, MedImmune
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
ASAP
|
|
|
|
|
|
|
|
Registration:
|
|
Contact Danielle Dalby on d.dalby@oxfordglobal.co.uk or call +44(0)1865 248 455. Alternatively book online here
|
|
|
E-mail:
|
|
d.dalby@oxfordglobal.co.uk
|
|
|
|
|
|
|
|
|